Canadian Sec - Free Realtime Quote CAD

DiagnosTear Technologies Inc. (DTR.CN)

0.2750
-0.0250
(-8.33%)
As of 9:30:00 AM EDT. Market Open.
Loading Chart for DTR.CN
  • Previous Close 0.3000
  • Open 0.2750
  • Bid 0.2800 x --
  • Ask 0.2800 x --
  • Day's Range 0.2750 - 0.2750
  • 52 Week Range 0.2000 - 0.7500
  • Volume 500
  • Avg. Volume 9,989
  • Market Cap (intraday) 16.167M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic solutions for eye diseases. It develops TeaRx Dry Eye, a CE-IVD approved test based on the TeaRx platform intended for the identification and monitoring of Dry Eye Syndrome (TeaR DES); TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis; and TeaRx Tear Collector, a proprietary microfluidic tear collector that allows non-invasive collection of 1 microliter of tear fluid and dilution in the assay buffer for downstream analytical testing. DiagnosTear Technologies Inc. was formerly known as Oceanview Technologies Inc. and changed its name to DiagnosTear Technologies Inc. The company was incorporated in 2023 and is headquartered in Rehovot, Israel.

diagnostear.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: DTR.CN

View More

Performance Overview: DTR.CN

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

DTR.CN
8.33%
S&P/TSX Composite index (^GSPTSE)
4.36%

1-Year Return

DTR.CN
61.27%
S&P/TSX Composite index (^GSPTSE)
15.29%

3-Year Return

DTR.CN
61.27%
S&P/TSX Composite index (^GSPTSE)
27.83%

5-Year Return

DTR.CN
61.27%
S&P/TSX Composite index (^GSPTSE)
75.51%

Compare To: DTR.CN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DTR.CN

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    17.64M

  • Enterprise Value

    15.26M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.26

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -0.4600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: DTR.CN

View More

Company Insights: DTR.CN

Research Reports: DTR.CN

View More